|Mr. James R. Neal||Chief Exec. Officer and Director||507.01k||N/A||61|
|Mr. Thomas Burns||Chief Financial Officer and Sr. VP of Fin.||392.93k||N/A||43|
|Mr. Denis J. Quinlan||Sr. Corp. Counsel and Corp. Sec.||N/A||N/A||N/A|
|Dr. Kirk W. Johnson Ph.D.||VP of Devel.||N/A||N/A||57|
XOMA Corporation discovers, develops, and commercializes antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The companys product candidates include X358, a human negative allosteric modulating insulin receptor antibody that is in Phase II proof-of-concept study for the treatment of patients with hypoglycemia due to congenital hyperinsulinism and hypoglycemia in post-bariatric surgery patients; X213, a allosteric inhibitor for the treatment of prolactinoma and anti-psychotic-induced hyperprolactinemia; and X129, a potent fragment of a monoclonal antibody for the treatment of patients with acute severe hypoglycemia. Its preclinical product candidates comprise interleukin 2 for the treatment of metastatic melanoma and renal cell carcinoma; and anti-parathyroid receptor, a G-protein-coupled receptor for the treatment of hyperparathyroidism and humoral hypercalcemia of malignancy. The company also licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. It has research and development collaboration and licensing agreements with Novartis AG; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.
XOMA Corporation’s ISS Governance QualityScore as of July 1, 2017 is 3. The pillar scores are Audit: 5; Board: 4; Shareholder Rights: 2; Compensation: 6.